The authors performed a phase I/II study combining gefitinib with vorinostat in previously treated non-small cell lung cancer (NSCLC). Treatment with 250 mg gefitinib daily with biweekly 400 mg/day vorinostat was feasible and well tolerated. In an unselected patient population, this combination dose did not improve PFS.

READ FULL ARTICLE Curated publisher From Mdlinx